Clinical Trial Update: Boceprevir/PegIFN α-2b/Riba in HCV+ Gt1 Menopausal Women, Nonresponders to PegIFN/Riba or Treatment-naives (MEN_BOC) [Phase 3]

View source ↗

Summary

Phase 3 study evaluating boceprevir in combination with pegylated interferon alfa-2b and ribavirin for genotype 1 chronic hepatitis C in menopausal women who ar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Boceprevir (boceprevir)
• Pegylated Interferon Alfa-2b (pegylated interferon alfa-2b)
• Ribavirin (ribavirin)

Snippet

Sponsor: University of Modena and Reggio Emilia | Conditions: Chronic Hepatitis C, Menopause | Phase 3 | Status: UNKNOWN